Ye Y - Search Results

1

Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy.

Jing Y, Liu J, Ye Y, Pan L, Deng H, Wang Y, Yang Y, Diao L, Lin SH, Mills GB, Zhuang G, Xue X, Han L. Jing Y, et al. Among authors: ye y. Nat Commun. 2020 Oct 2;11(1):4946. doi: 10.1038/s41467-020-18742-9. Nat Commun. 2020. PMID: 33009409 Free PMC article.

2

PancanQTL: systematic identification of cis-eQTLs and trans-eQTLs in 33 cancer types.

Gong J, Mei S, Liu C, Xiang Y, Ye Y, Zhang Z, Feng J, Liu R, Diao L, Guo AY, Miao X, Han L. Gong J, et al. Among authors: ye y. Nucleic Acids Res. 2018 Jan 4;46(D1):D971-D976. doi: 10.1093/nar/gkx861. Nucleic Acids Res. 2018. PMID: 29036324 Free PMC article.

3

Comprehensive Characterization of Alternative Polyadenylation in Human Cancer.

Xiang Y, Ye Y, Lou Y, Yang Y, Cai C, Zhang Z, Mills T, Chen NY, Kim Y, Muge Ozguc F, Diao L, Karmouty-Quintana H, Xia Y, Kellems RE, Chen Z, Blackburn MR, Yoo SH, Shyu AB, Mills GB, Han L. Xiang Y, et al. Among authors: ye y. J Natl Cancer Inst. 2018 Apr 1;110(4):379-389. doi: 10.1093/jnci/djx223. J Natl Cancer Inst. 2018. PMID: 29106591 Free PMC article.

4

A Pan-cancer Analysis of the Expression and Clinical Relevance of Small Nucleolar RNAs in Human Cancer.

Gong J, Li Y, Liu CJ, Xiang Y, Li C, Ye Y, Zhang Z, Hawke DH, Park PK, Diao L, Putkey JA, Yang L, Guo AY, Lin C, Han L. Gong J, et al. Among authors: ye y. Cell Rep. 2017 Nov 14;21(7):1968-1981. doi: 10.1016/j.celrep.2017.10.070. Cell Rep. 2017. PMID: 29141226 Free article.

5

The Genomic Landscape and Pharmacogenomic Interactions of Clock Genes in Cancer Chronotherapy.

Ye Y, Xiang Y, Ozguc FM, Kim Y, Liu CJ, Park PK, Hu Q, Diao L, Lou Y, Lin C, Guo AY, Zhou B, Wang L, Chen Z, Takahashi JS, Mills GB, Yoo SH, Han L. Ye Y, et al. Cell Syst. 2018 Mar 28;6(3):314-328.e2. doi: 10.1016/j.cels.2018.01.013. Epub 2018 Mar 7. Cell Syst. 2018. PMID: 29525205 Free PMC article.

6

TRIM59 promotes breast cancer motility by suppressing p62-selective autophagic degradation of PDCD10.

Tan P, Ye Y, He L, Xie J, Jing J, Ma G, Pan H, Han L, Han W, Zhou Y. Tan P, et al. Among authors: ye y. PLoS Biol. 2018 Nov 8;16(11):e3000051. doi: 10.1371/journal.pbio.3000051. eCollection 2018 Nov. PLoS Biol. 2018. PMID: 30408026 Free PMC article.

7

Maximizing the Utility of Cancer Transcriptomic Data.

Xiang Y, Ye Y, Zhang Z, Han L. Xiang Y, et al. Among authors: ye y. Trends Cancer. 2018 Dec;4(12):823-837. doi: 10.1016/j.trecan.2018.09.009. Epub 2018 Oct 14. Trends Cancer. 2018. PMID: 30470304 Review.

8

Global analysis of tRNA and translation factor expression reveals a dynamic landscape of translational regulation in human cancers.

Zhang Z, Ye Y, Gong J, Ruan H, Liu CJ, Xiang Y, Cai C, Guo AY, Ling J, Diao L, Weinstein JN, Han L. Zhang Z, et al. Among authors: ye y. Commun Biol. 2018 Dec 21;1:234. doi: 10.1038/s42003-018-0239-8. eCollection 2018. Commun Biol. 2018. PMID: 30588513 Free PMC article.

9

Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression.

Hu Q, Ye Y, Chan LC, Li Y, Liang K, Lin A, Egranov SD, Zhang Y, Xia W, Gong J, Pan Y, Chatterjee SS, Yao J, Evans KW, Nguyen TK, Park PK, Liu J, Coarfa C, Donepudi SR, Putluri V, Putluri N, Sreekumar A, Ambati CR, Hawke DH, Marks JR, Gunaratne PH, Caudle AS, Sahin AA, Hortobagyi GN, Meric-Bernstam F, Chen L, Yu D, Hung MC, Curran MA, Han L, Lin C, Yang L. Hu Q, et al. Among authors: ye y. Nat Immunol. 2019 Jul;20(7):835-851. doi: 10.1038/s41590-019-0400-7. Epub 2019 Jun 3. Nat Immunol. 2019. PMID: 31160797 Free PMC article.

10

Circadian period 2: a missing beneficial factor in sickle cell disease by lowering pulmonary inflammation, iron overload, and mortality.

Adebiyi MG, Zhao Z, Ye Y, Manalo J, Hong Y, Lee CC, Xian W, McKeon F, Culp-Hill R, D' Alessandro A, Kellems RE, Yoo SH, Han L, Xia Y. Adebiyi MG, et al. Among authors: ye y. FASEB J. 2019 Sep;33(9):10528-10537. doi: 10.1096/fj.201900246RR. Epub 2019 Jun 29. FASEB J. 2019. PMID: 31260634 Free PMC article.

Overall, we demonstrate that Per1/Per2 is beneficial to counteract elevated systemic inflammation, lung tissue inflammation, and iron overload in SCD.-Adebiyi, M. G., Zhao, Z., Ye, Y., Manalo, J., Hong, Y., Lee, C. C., Xian, W., McKeon, F., Culp-Hill, R., D' …

Overall, we demonstrate that Per1/Per2 is beneficial to counteract elevated systemic inflammation, lung tissue inflammation, and iron overlo …

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

10,660 results

Search Page